# NP137

Source: https://onco.cc/drugs/np137/  
OnCo record `np137` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NP137 is a monoclonal antibody from NETRIS Pharma, in registered phase 2 trials for endometrial cancer, cervical cancer.

## Summary

NP137 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by NETRIS Pharma, in endometrial cancer, cervical cancer. A monoclonal antibody, as described in the registry record. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: NP137
- Modality: Monoclonal antibody
- Mechanism: A monoclonal antibody, as described in the registry record.

## Sources

- ClinicalTrials.gov: trials of NP137: https://clinicaltrials.gov/search?intr=NP137

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- trials: [GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab](https://onco.cc/trials/nct04652076/)

---
JSON: https://onco.cc/api/v1/entities/np137.json